EU/3/06/413:

budesonide

Table of contents

Overview

On 3 November 2006, orphan designation (EU/3/06/413) was granted by the European Commission to Dr Falk Pharma GmbH, Germany, for budesonide (oral use) for the treatment of Graft-versus-Host disease.

Key facts

Active substance
budesonide
Intented use
Treatment of graft-versus-host disease
Date of designation
03/11/2006
Orphan designation status
Positive
EU designation number
EU/3/06/413

Sponsor's contact details

Dr Falk Pharma GmbH
Leinenweberstrasse 5
D-79041 Freiburg i. Br
Germany
Telephone: +49 76 11 51 40
Telefax: +49 76 11 51 43 21
E-mail: zentrale@drfalkpharma.de

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating